# Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC)

> **NCT06549465** · PHASE2 · RECRUITING · sponsor: **Convergent Therapeutics** · enrollment: 60 (estimated)

## Conditions studied

- PSMA PET-Positive Castration-Resistant Prostate Cancer

## Interventions

- **BIOLOGICAL:** In-111 rosopatamab tetraxetan
- **BIOLOGICAL:** 45 kBq/kg Ac-225 rosopatamab tetraxetan
- **BIOLOGICAL:** 55 kBq/kg Ac-225 rosopatamab tetraxetan
- **BIOLOGICAL:** 60 kBq/kg Ac-225 rosopatamab tetraxetan

## Key facts

- **NCT ID:** NCT06549465
- **Lead sponsor:** Convergent Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-06
- **Primary completion:** 2025-12
- **Final completion:** 2027-04
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06549465

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06549465, "Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06549465. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*